Garnero, P., Buchs, N., Zekri, J. et al. (3 more authors) (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. British Journal of Cancer, 82 (4). pp. 858-864. ISSN 0007-0920
Abstract
The incidence of gastro-oesophageal junction (GEJ) adenocarcinoma is increasing in Western countries and prognosis is poor since metastasis is most often present at diagnosis. We examined samples from 87 resected type II GEJ adenocarcinomas, 30 of these with endoscopic diagnostic biopsy material, to evaluate transforming growth factor alpha (TGF-α) expression and p53 overexpression by immunohistochemistry and in situ hybridization (for TGF-α), in relation to biological and clinical behaviour. TGF-α messenger RNA (mRNA) and protein were detectable in neoplastic cells in 56% and 64% cases respectively. TGF-α mRNA was detected in intra- and peritumoral lymphocytes and those of metastatic lymph nodes. TGF-α protein expression was significantly associated with tumour progression (P = 0.025) and lymph node metastasis (P< 0.05). The strong TGF-α expression found in neoplastic cells inside blood and lymphatic vessels and in metastatic localizations suggests that TGF-α-positive GEJ adenocarcinomas could have a more aggressive biological phenotype. The expression of TGF-α mRNA and protein in both inflammatory and neoplastic cells indicates that TGF-α is directly synthesized by both cell compartments. Finally, since TGF-α expression was associated with lymph node metastasis, its detection in preoperative perendoscopic biopsies might identify patients with more aggressive tumours who may need additional therapy, including neo-adjuvant treatment.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2000 Cancer Research Campaign. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/. |
Keywords: | bone markers; prostate cancer; bone metastases; type I collagen; bisphosphonate; hormone replacement therapy; c-terminal telopeptide; pyridinium cross-links; i collagen; degradation products; alkaline-phosphatase; pagets-disease; urinary pyridinoline; biochemical markers; diagnostic-value |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 08 Aug 2016 11:29 |
Last Modified: | 08 Aug 2016 11:32 |
Published Version: | http://dx.doi.org/10.1054/bjoc.1999.1012 |
Status: | Published |
Publisher: | Cancer Research UK |
Refereed: | Yes |
Identification Number: | 10.1054/bjoc.1999.1012 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:97855 |
Download
Licence: CC-BY-NC-SA 3.0